Apitoria, a wholly-owned subsidiary of Aurobindo Pharma, stands as a testament to focused efforts in the API business, aiming to establish itself as the premier partner for prominent pharmaceutical companies worldwide. Stemming from the vision of Aurobindo Pharma, a global powerhouse in the pharmaceutical realm, Apitoria specializes in the production of Active Pharmaceutical Ingredients (APIs), fostering trust and reliability within the industry aiming to be a trusted partner for pharmaceutical companies.

We have a state-of-the-art API R&D Center and 10 manufacturing facilities with a total installed API capacity of 19,000 MT. Apitoria offers a diverse range of API products across various categories, including antibiotics, CNS & CVS, complex molecules, antidiabetic, oncology, and more.

Apitoria, a regulatory prowess is reflected in its diverse portfolio, Comprising of 250+ molecules with numerous filings globally including US Drug Master Files (DMFs), Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEPs), Canadian DMFs, Korean DMFs, Japanese DMFs and more. In alignment with Aurobindo Pharma's legacy in the pharmaceutical domain, Apitoria continues to uphold the foundation of innovation and quality to ensure it becomes the most preferred partner.